期刊
JOURNAL OF MEDICAL MICROBIOLOGY
卷 62, 期 -, 页码 451-456出版社
SOC GENERAL MICROBIOLOGY
DOI: 10.1099/jmm.0.047472-0
关键词
-
类别
资金
- National Science & Technology Major Specific Projects of China for 'Significant Creation of New Drugs' [2012ZX09102301-013]
- Science & Technology Projects of Shenyang, China [F11-264-1-11]
As a superantigen, staphylococcal enterotoxin C2 (SEC2) has commonly been used as an antitumour immunotherapy agent in China. However, the clinical application of SEC2 has been hampered by its pyrogenic toxicity and the presence of neutralizing antibody in patients. Thus, an improvement in its superantigen-based immunotherapy is highly needed. In this study, a truncated SEC2 mutant, SEC(14-128), was constructed without the N-terminal 13 and C-terminal 111 aa. This mutant retained T-cell proliferation and antitumour activities in in vitro experiments. However, it induced a significantly decreased release of the main inflammatory cytokines inerleukin-2 and gamma interferon. Moreover, SEC(14-128) exhibited reduced toxicity and affinity to anti-SEC2 IgG compared with native SEC2. Based on the considerable antitumour activity and low toxicity, it is proposed that the mutant SEC(14-128) could be a potential candidate for cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据